STOCK TITAN

Carlsmed (NASDAQ: CARL) investors back board nominees and Ernst & Young

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Carlsmed, Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026, where stockholders voted on director elections and auditor ratification. Niall Casey and Philip Young were elected as Class I directors to serve until the 2029 annual meeting or until successors are elected and qualified.

Casey received 19,627,716 votes for and 1,352,117 votes withheld, while Young received 19,510,686 votes for and 1,469,147 votes withheld, with 4,628,080 broker non-votes on each director proposal. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 25,571,065 votes for, 5,858 against, and 30,990 abstentions.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Votes for Niall Casey 19,627,716 votes Election as Class I director at 2026 Annual Meeting
Votes withheld for Niall Casey 1,352,117 votes Director election withholding tally
Votes for Philip Young 19,510,686 votes Election as Class I director at 2026 Annual Meeting
Votes withheld for Philip Young 1,469,147 votes Director election withholding tally
Broker non-votes on director elections 4,628,080 votes Broker non-votes for each Class I director proposal
Votes for auditor ratification 25,571,065 votes Ratifying Ernst & Young LLP for fiscal year ending December 31, 2026
Votes against auditor ratification 5,858 votes Opposition to Ernst & Young LLP ratification
Abstentions on auditor ratification 30,990 votes Abstaining votes on Ernst & Young LLP ratification
broker non-votes financial
"Niall Casey ... 1,352,117 ... 4,628,080 broker non-votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
definitive proxy statement regulatory
"each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
Schedule 14A regulatory
"described in more detail in the Company’s definitive proxy statement on Schedule 14A"
Schedule 14A is a document that companies file with regulators to share important information with shareholders before a big vote, like approving a merger or election of directors. It matters because it helps investors understand what’s happening so they can make informed decisions about the company’s future.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false0001794546June 3, 202600017945462026-06-032026-06-03

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2026

 

 

Carlsmed, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-42756

83-1081863

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1800 Aston Ave, Suite 100

 

Carlsbad, California

 

92008

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (760) 766-1923

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.00001 par value per share

 

CARL

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

Carlsmed, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 3, 2026. At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 22, 2026. The vote totals noted below are final voting results from the Annual Meeting.

 

Proposal 1

The Company’s stockholders elected the following two Class I directors to serve on the Company’s board of directors until the 2029 annual meeting of stockholders, or until their successors are duly elected and qualified.

 

 

Name

 

Votes For

 

 

Votes Withheld

 

 

Broker Non-Votes

 

Niall Casey

 

 

19,627,716

 

 

 

1,352,117

 

 

 

4,628,080

 

Philip Young

 

 

19,510,686

 

 

 

1,469,147

 

 

 

4,628,080

 

 

Proposal 2

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

 

 

Votes For

 

 

Votes Against

 

 

Abstentions

 

 

25,571,065

 

 

 

5,858

 

 

 

30,990

 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

Date: June 3, 2026

 

Carlsmed, Inc.

 

 

 

 

 

 

By:

/s/ Michael Cordonnier

 

 

 

Michael Cordonnier

 

 

 

Chief Executive Officer and President


FAQ

What did Carlsmed (CARL) stockholders vote on at the 2026 annual meeting?

Carlsmed stockholders voted on two proposals: electing two Class I directors and ratifying Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Both proposals received sufficient support to pass.

Which directors were elected at Carlsmed (CARL)’s 2026 Annual Meeting?

Stockholders elected Niall Casey and Philip Young as Class I directors. They will serve on the board of directors until the 2029 annual meeting of stockholders, or until their successors are duly elected and qualified, according to the meeting results.

How many votes did Carlsmed (CARL) director nominees receive in 2026?

Niall Casey received 19,627,716 votes for and 1,352,117 votes withheld. Philip Young received 19,510,686 votes for and 1,469,147 votes withheld. Each director proposal had 4,628,080 broker non-votes recorded in the final tally.

Was Ernst & Young LLP ratified as Carlsmed (CARL)’s auditor for 2026?

Yes. Stockholders ratified Ernst & Young LLP as Carlsmed’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 25,571,065 votes for, 5,858 votes against, and 30,990 abstentions recorded.

When was Carlsmed (CARL)’s 2026 Annual Meeting of Stockholders held?

Carlsmed held its 2026 Annual Meeting of Stockholders on June 3, 2026. At this meeting, stockholders considered and voted on the election of two Class I directors and the ratification of Ernst & Young LLP as the company’s independent auditor for 2026.

Filing Exhibits & Attachments

1 document